Thomas Shrader
Stock Analyst at BTIG
(3.18)
# 1,041
Out of 5,180 analysts
92
Total ratings
45.24%
Success rate
1.96%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Reiterates: Buy | $147 | $68.45 | +114.76% | 5 | Mar 30, 2026 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Buy | $8 | $2.19 | +265.30% | 5 | Mar 26, 2026 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $4 | $2.11 | +89.57% | 4 | Mar 26, 2026 | |
| DNLI Denali Therapeutics | Maintains: Buy | $36 → $38 | $18.08 | +110.18% | 6 | Mar 25, 2026 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $2.09 | +1,096.17% | 4 | Mar 24, 2026 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $31.77 | +22.76% | 3 | Mar 19, 2026 | |
| HROW Harrow | Reiterates: Buy | $63 | $33.30 | +89.19% | 4 | Mar 18, 2026 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $2.56 | +212.50% | 4 | Mar 16, 2026 | |
| ALEC Alector | Upgrades: Buy | $6 | $2.02 | +197.03% | 5 | Mar 10, 2026 | |
| IRD Opus Genetics | Maintains: Buy | $7 → $12 | $4.35 | +175.86% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.19 | +740.34% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $89 | $54.96 | +61.94% | 7 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $28 | $19.98 | +40.14% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $8.09 | +134.86% | 1 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.09 | +97.78% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $3.78 | +323.28% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.68 | +435.71% | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $6.90 | +233.33% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.80 | +400.00% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $5.24 | +167.18% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $12.88 | +1,452.80% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $5.42 | +1,007.01% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $4.96 | +41.13% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.15 | +8,341.56% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.18 | +4,240.43% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.05 | +295.06% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.87 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.41 | +112.77% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $187.57 | +84.46% | 3 | Feb 21, 2019 |
Bright Minds Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $147
Current: $68.45
Upside: +114.76%
Acumen Pharmaceuticals
Mar 26, 2026
Reiterates: Buy
Price Target: $8
Current: $2.19
Upside: +265.30%
Ovid Therapeutics
Mar 26, 2026
Reiterates: Buy
Price Target: $4
Current: $2.11
Upside: +89.57%
Denali Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $18.08
Upside: +110.18%
NRx Pharmaceuticals
Mar 24, 2026
Reiterates: Buy
Price Target: $25
Current: $2.09
Upside: +1,096.17%
Stoke Therapeutics
Mar 19, 2026
Reiterates: Buy
Price Target: $39
Current: $31.77
Upside: +22.76%
Harrow
Mar 18, 2026
Reiterates: Buy
Price Target: $63
Current: $33.30
Upside: +89.19%
AC Immune
Mar 16, 2026
Reiterates: Buy
Price Target: $8
Current: $2.56
Upside: +212.50%
Alector
Mar 10, 2026
Upgrades: Buy
Price Target: $6
Current: $2.02
Upside: +197.03%
Opus Genetics
Mar 2, 2026
Maintains: Buy
Price Target: $7 → $12
Current: $4.35
Upside: +175.86%
Feb 26, 2026
Reiterates: Buy
Price Target: $10
Current: $1.19
Upside: +740.34%
Feb 26, 2026
Maintains: Buy
Price Target: $85 → $89
Current: $54.96
Upside: +61.94%
Feb 17, 2026
Maintains: Buy
Price Target: $27 → $28
Current: $19.98
Upside: +40.14%
Jan 20, 2026
Reiterates: Buy
Price Target: $19
Current: $8.09
Upside: +134.86%
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $8.09
Upside: +97.78%
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $3.78
Upside: +323.28%
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $1.68
Upside: +435.71%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $6.90
Upside: +233.33%
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $1.80
Upside: +400.00%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $5.24
Upside: +167.18%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $12.88
Upside: +1,452.80%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $5.42
Upside: +1,007.01%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $4.96
Upside: +41.13%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.15
Upside: +8,341.56%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.18
Upside: +4,240.43%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $4.05
Upside: +295.06%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.87
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.41
Upside: +112.77%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $187.57
Upside: +84.46%